Occult hepatitis B virus infection (OBI) represents a distinct clinical entity defined by the presence of replication-competent viral DNA in the liver of individuals who test negative for the hepatitis B surface antigen (HBsAg). Because viral replication remains in a low state, managing OBI carries critical implications for blood transfusion safety, liver transplantation, and immunosuppressed patients worldwide.
Understanding Occult Hepatitis B Infection
Episomal Persistence and Diagnostic Hurdles
OBI is classified by the persistence of episomal covalently closed circular DNA (cccDNA) in hepatic tissue despite standard serological tests missing the surface antigen. Serum viral loads in these patients usually stay below 200 International Units per milliliter (IU/mL), meaning viremia flickers intermittently. Consequently, detecting viral DNA depends heavily on the sensitivity of the assay used and whether the blood samples analyzed were collected at one or more time points, creating diagnostic challenges for clinical laboratories.
Transfusion Safety and Donor Screening
The detection of hepatitis B core antibodies (anti-HBc) in blood donors frequently serves as a marker for occult infection. Blood units from anti-HBc positive, HBsAg-negative donors can still transmit the virus to transfusion recipients.
Oncogenic Potential and Reactivation Risks
Occult hepatitis B maintains pro-oncogenic properties of the “overt” infection, contributing to the development of hepatocellular carcinoma. Furthermore, OBI accelerates chronic liver disease progression toward cirrhosis, especially in patients with hepatitis C virus. When individuals with occult infections experience immunosuppression, the virus can reactivate and cause possible development of even fulminant hepatitis.
Worldwide Prevalence and Assay Standardization
Global prevalence rates of OBI vary widely depending on geographic areas, local parenteral risk factors, and the assays used for HBsAg and HBV DNA detection.
Worth a look